Ingredient reference
About Levonorgestrel
Levonorgestrel is a progestin. This catalogue record is the daily progestogen-only tablet taken continuously, which is a different product from the single high-dose emergency tablet recorded separately as LP-104. The two differ in strength, in how they are taken and in what they are for, and must not be described as interchangeable.
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
A daily progestogen-only tablet is taken every day without a break, and its effect depends on consistent timing. Suitability, interactions, bleeding-pattern expectations and what to do about a missed tablet are matters for the approved label and for a qualified prescriber. This record identifies an ingredient, a strength and a presentation only.
Important safety considerations
Irregular bleeding is the most common effect and may persist. Headache, breast tenderness, mood change, acne and abdominal discomfort can occur. New severe abdominal pain, a missed period after irregular bleeding, or symptoms suggesting pregnancy need prompt assessment. Interacting medicines, including some anticonvulsants and rifamycins, can reduce effectiveness.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The catalogue identifies a low-dose tablet supplied in a 28-tablet continuous cycle pack. Tablet appearance, excipients, pack labelling and day-marking are formulation- and market-specific and require controlled product documentation. The emergency presentation (LP-104) has a separate specification.
Keep the medicine in the labelled original pack with its leaflet so the day sequence stays readable. Check the expiry date and pack integrity before use. Storage conditions and shelf life follow the approved product label.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm which presentation is intended before any clinical discussion: a daily progestogen-only tablet and an emergency tablet are not the same product. Review interacting medicines, medical history and the patient's ability to take a tablet at a consistent time.
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Levonorgestrel
- Dosage form / presentation
- Progestin-only tablet
- Catalogue strength
- 30 mcg
- Catalogue pack
- 28-tablet cycle pack
- Portfolio category
- Women's Health
Layer 02
Unresolved product-specific fields
- A daily progestogen-only tablet and an emergency tablet are different medicines and are not interchangeable.
- Missed-tablet handling, interacting medicines and bleeding-pattern expectations follow the approved label of the registered product.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NHS: progestogen-only pillpublic health service information
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
Product enquiry
Documentation & regulatory status
For LP-224, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
